Frequency of certain single-nucleotide polymorphisms and duplication of CYP2D6 in the Jordanian population

Genetic Testing and Molecular Biomarkers

Volumn 16, Issue 10, 2012, Pages 1201-1205

  Zihlif, Malek ^a   Imraish, Amer ^a   Irshaid, Yacoub M ^a  

^a UNIVERSITY OF JORDAN   (Jordan)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2D6;

ADULT; ARTICLE; FEMALE; GENE DUPLICATION; GENE FREQUENCY; GENE IDENTIFICATION; GENOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; MALE; NORMAL HUMAN; POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; ASIAN CONTINENTAL ANCESTRY GROUP; CYTOCHROME P-450 CYP2D6; FEMALE; GENE DUPLICATION; GENE FREQUENCY; GENOTYPE; HUMANS; JORDAN; MALE; MUTATION; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 84867521268     PISSN: 19450265     EISSN: 19450257     Source Type: Journal    
DOI: 10.1089/gtmb.2012.0122     Document Type: Article

References (30)

1. Aklillu E, Persson I, Bertilsson L, et al. (1996) Frequent distribution of ultrarapid metabolizers of debrisoquine in an Ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles. J Pharmacol Exp Ther 278:441-446.
2. Benny K, Abraham C (2001) Genetic polymorphism of CYP2D6. Indian J Pharmacol 33:147-169.
3. Bernal ML, Sinues B, Johansson I, et al. (1999) Ten percent of North Spanish individuals carry duplicated or triplicated CYP2D6 genes associated with ultrarapid metabolism of debrisoquine. Pharmacogenetics 9:657-660.
4. Bernard S, Neville K, Nguyen A, et al. (2006) Interethnic differences in genetic polymorphisms of CYP2D6 in the U.S. population: clinical implications. Oncologist 11:126-135.
5. Bradford LD (2002) CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. Pharmaco-genomics 3:229-243.
6. Crews KR, Gaedigk A, Dunnenberger HM, et al. (2012) Clinical pharmacogenetics implementation consortium (CPIC) guidelines for codeine therapy in the context of cytochrome P450 2D6 (CYP2D6) genotype. Clin Pharmacol Ther 91:321-326.
7. Evans WE, Relling MV (2004) Moving towards individualized medicine with pharmacogenomics. Nature 429:464-468.
8. Fuselli S, Dupanloup I, Frigato E, et al. (2004) Molecular diversity at the CYP2D6 locus in the Mediterranean region. Eur J Hum Genet 12:916-924.
9. Hadidi H, Cholerton S, Monkman S, et al. (1994) Debrisoquine 4-hydroxylation (CYP2D6) polymorphism in Jordanians. Pharmacogenetics 4:159-161.
10. Ingelman-Sundberg M (2005) Genetic polymorphisms of cyto-chrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics J 5:6-13.
11. Ingelman-Sundberg M, Evans W (2001) Unravelling the functional genomics of the human CYP2D6 gene locus. Pharma-cogenetics 11:553-554.
12. Ingelman-Sundberg M, Oscarson M, McLellan RA (1999) Polymorphic human cytochrome P450 enzymes: an opportunity for individualized drug treatment. Trends Pharmacol Sci 20:342-349.
13. Ingelman-Sundberg M, Sim SC, Gomez A, et al. (2007) Influence of cytochrome P450 polymorphisms on drug therapies: phar-macogenetic, pharmacoepigenetic and clinical aspects. Pharmacol Ther 116:496-526.
14. Jann MW, Cohen LJ (2000) The influence of ethnicity and anti-depressant pharmacogenetics in the treatment of depression. Drug Metabol Drug Interact 16:39-67.
15. Kitada M (2003) Genetic polymorphism of cytochrome P450 enzymes in Asian populations: focus on CYP2D6. Int J Clin Pharmacol Res 23:31-35.
16. Koseler A, Ilcol YO, Ulus IH (2007) Frequency of mutated allele CYP2D64 in the Turkish population. Pharmacology 79:203-206.
17. Laika B, Leucht S, Heres S, et al. (2009) Intermediate metabolizer: increased side effects in psychoactive drug therapy. The key to cost-effectiveness of pretreatment CYP2D6 screening: CYP2D6 IMs and side effects. Pharmacogenomics J 9:395-403.
18. Lovlie R, Daly A, Molven A, et al. (1996) Ultrarapid metabolizers of debrisoquine: characterization and PCR-based detection of alleles with duplication of the CYP2D6 gene. FEBS 392:30-34.
19. Ma MK, Woo MH, McLeod HL (2002) Genetic basis of drug metabolism. Am Health Syst Pharm 59:2061-2069.
20. Madadi P, Koren G, Cairns J, et al. (2007) Safety of codeine during breastfeeding: fatal morphine poisoning in the breastfed neonate of a mother prescribed codeine. Can Fam Physician 53:33-35.
21. Mulder H, Herder A, Frederik W (2006) The impact of cyto-chrome P450-2D6 genotype on the use and interpretation of therapeutic drug monitoring in long-stay patients treated with antidepressant and antipsychotic drugs in daily psychiatric practice. Pharmacoepidemiol Drug Saf 15:107-114.
22. Oscarson M, Hidestrand M, Johansson I, et al. (1997) A combination of mutations in the CYP2D617 allele causes alterations in enzyme function. Mol Pharmacol 32:1034-1040.
23. Risch N, Burchard E, Ziv E, et al. (2002) Categorization of humans in biomedical research: genes, race and disease. Genome Biol 3:comment2007.
24. Scordo MG, Caputi AP, D'Arrigo C, et al. (2004) Allele and genotype frequencies of CYP2C9, CYP2C19 and CYP2D6 in an Italian population. Pharmacol Res 50:195-200.
25. Tateishi T, Chiba M, Ariyoshi N, et al. (1999) Analysis of the CYP2D6 gene in relation to dextromethorphan O-demethyla-tion capacity in a Japanese population. Clin Pharmacol Therapeut 65:570-575.
26. Teh LK, Bertilsson L (2012) Pharmacogenomics of CYP2D6: molecular genetics, interethnic differences and clinical importance. Drug Metab Pharmacokinet 27:55-67.
27. Theophilus N, Chandrasekaran A, Sam S, et al. (2006) CYP2D6 genetic polymorphism in south Indian populations. Biol Pharm Bull 29:1655-1658.
28. Tod M, Goutelle S, Gagnieu MC (2011) Genotype-based quantitative prediction of drug exposure for drugs metabolized by CYP2D6. Clin Pharmacol Ther 90:582-587.
29. Zhou SF (2009) Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II. Clin Pharmacokinet 48:761-804.
30. Zuo LJ, Guo T, Xia DY, et al. (2012) Allele and genotype frequencies of CYP3A4, CYP2C19, and CYP2D6 in Han, Uighur, Hui, and Mongolian Chinese populations. Genet Test Mol Biomarkers 16:102-108.